These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33687270)

  • 1. Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2).
    Samuel M; Tardif JC
    Future Cardiol; 2021 May; 17(3):411-414. PubMed ID: 33687270
    [No Abstract]   [Full Text] [Related]  

  • 2. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from COLCOT and LoDoCo2: colchicine for secondary prevention in coronary artery disease.
    Bouabdallaoui N; Blondeau L; Tardif JC
    Eur Heart J; 2021 Jul; 42(28):2800-2801. PubMed ID: 33496313
    [No Abstract]   [Full Text] [Related]  

  • 4. Update on the Inflammatory Hypothesis of Coronary Artery Disease.
    Boland J; Long C
    Curr Cardiol Rep; 2021 Jan; 23(2):6. PubMed ID: 33409720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
    Ajala ON; Everett BM
    Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine.
    Andreotti F; Maggioni AP; Campeggi A; Iervolino A; Scambia G; Massetti M
    Eur Heart J Suppl; 2021 Oct; 23(Suppl E):E13-E18. PubMed ID: 34650351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?].
    Hoogeveen RM; Stroes ESG; Cornel JH
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation and ischemic heart disease: The next therapeutic target?
    Vilela EM; Fontes-Carvalho R
    Rev Port Cardiol (Engl Ed); 2021 Oct; 40(10):785-796. PubMed ID: 34857118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colchicine in the Management of Acute and Chronic Coronary Artery Disease.
    Bouabdallaoui N; Tardif JC
    Curr Cardiol Rep; 2021 Jul; 23(9):120. PubMed ID: 34269908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colchicine for the treatment of coronary artery disease.
    Aimo A; Pascual-Figal DA; Barison A; Cediel G; Vicente ÁH; Saccaro LF; Emdin M; Bayes-Genis A
    Trends Cardiovasc Med; 2021 Nov; 31(8):497-504. PubMed ID: 33096241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation and ischemic heart disease: The next therapeutic target?
    Vilela EM; Fontes-Carvalho R
    Rev Port Cardiol (Engl Ed); 2021 Aug; ():. PubMed ID: 34456098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies.
    Banach M; Penson PE
    Curr Atheroscler Rep; 2021 May; 23(7):32. PubMed ID: 33970350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
    Bouabdallaoui N; Tardif JC; Waters DD; Pinto FJ; Maggioni AP; Diaz R; Berry C; Koenig W; Lopez-Sendon J; Gamra H; Kiwan GS; Blondeau L; Orfanos A; Ibrahim R; Grégoire JC; Dubé MP; Samuel M; Morel O; Lim P; Bertrand OF; Kouz S; Guertin MC; L'Allier PL; Roubille F
    Eur Heart J; 2020 Nov; 41(42):4092-4099. PubMed ID: 32860034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review.
    Zhang FS; He QZ; Qin CH; Little PJ; Weng JP; Xu SW
    Acta Pharmacol Sin; 2022 Sep; 43(9):2173-2190. PubMed ID: 35046517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians.
    Marquis-Gravel G; Goodman SG; Anderson TJ; Bell AD; Bewick D; Cox J; Grégoire JC; Gupta A; Huynh T; Kertland H; Kouz S; L'Allier PL; Madan M; Mancini GBJ; McPherson R; So DYF; Welsh RC; Wong G; Tardif JC
    Can J Cardiol; 2021 Nov; 37(11):1837-1845. PubMed ID: 34418482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Colchicine a New Game-Changer in Patients With Acute Coronary Syndrome?
    Nawabi AQ; Hassan W; Chen L; Shaikh N; Abbas K; Zehra FT
    Cureus; 2022 Mar; 14(3):e22874. PubMed ID: 35399435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
    Ridker PM
    Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COLCOT and CANTOS: piecing together the puzzle of inflammation and cardiovascular events.
    Wohlford GF; Van Tassell BW; Ravindra K; Abbate A
    Minerva Cardioangiol; 2020 Feb; 68(1):5-8. PubMed ID: 31789011
    [No Abstract]   [Full Text] [Related]  

  • 19. Combating Inflammation in Cardiovascular Disease.
    Sethwala AM; Goh I; Amerena JV
    Heart Lung Circ; 2021 Feb; 30(2):197-206. PubMed ID: 33039279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Inflammation After Myocardial Infarction.
    Mahtta D; Sudhakar D; Koneru S; Silva GV; Alam M; Virani SS; Jneid H
    Curr Cardiol Rep; 2020 Aug; 22(10):110. PubMed ID: 32770365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.